Table 4. Overall survival of 131 lung adenocarcinoma patients in relation to clinical covariates and immunohistochemistry of protein pairs.

A. Univariate Cox regression
Variable	Subset	Hazard ratio (95% CI)	p-value
Stage	III–IV/I–II	2.69 (1.66 - 4.37)	0.000
Age	age>65/age≦65	2.21 (1.29 - 3.78)	0.004
Sex	male/female	1.99 (1.22 - 3.26)	0.006
RAD54B	↑/↓a	2.39 (1.45 - 3.94)	0.001
(BRCA1(C), RAD54B)	(↓,↑)/otherwise	2.81 (1.66 - 4.75)	0.000
(FEN1(N), RAD54B)	(↑,↑)/otherwise	2.61 (1.53 - 4.43)	0.000
(PARP1(N), RAD54B)	(↑,↑)/otherwise	2.40 (1.41 - 4.08)	0.001
B. Multivariate Cox regressionb
Variable	Subset	Hazard ratio (95% CI)	p-value
RAD54B and three clinical factors
RAD54B	↑/↓	1.82 (1.09 - 3.02)	0.021
Age	age>65/age≦65	2.75 (1.55 - 4.88)	0.001
Stage	III–IV/I–II	3.08 (1.79 - 5.29)	0.000
BRCA1-RAD54B and three clinical factors
(BRCA1, RAD54B)	(↓,↑)/otherwise	2.19 (1.28 - 3.73)	0.004
Age	age>65/age≦65	2.66 (1.50 - 4.75)	0.001
Stage	III–IV/I–II	3.20 (1.80 - 5.68)	0.000
FEN1(N)-RAD54B and three clinical factors
(FEN1(N), RAD54B)	(↑,↑)/otherwise	2.12 (1.22 - 3.68)	0.007
Age	age>65/age≦65	2.60 (1.46 - 4.65)	0.001
Stage	III–IV/I–II	3.24 (1.89 - 5.54)	0.000
PARP1-RAD54B and three clinical factors
(PARP1, RAD54B)	(↑,↑)/otherwise	1.90 (1.13 - 3.19)	0.016
Age	age>65/age≦65	2.49 (1.39 - 4.46)	0.002
Stage	III–IV/I–II	2.88 (1.66 - 4.98)	0.000

^aThe symbols “↑”and “↓”denote over- and under-expression of IHC, respectively of the corresponding protein.

^bVariables were selected by stepwise selection and AIC.